Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA), the world’s leading generics drugmaker, and Swiss chemicals and drug company Lonza (SIX: LONN) have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimiars.
The decision follows a strategic review of the Teva-Lonza Joint Venture (TL-JV), which began in 2009 ( The Pharma Letter January 26, 2009) and a joint statement said it will enable both companies to advance their own strategies.
It added that both companies will continue to explore opportunities to maximize the value of the investments and progress that the joint venture has made to this point, and remain in agreement that affordable, efficacious and safe biosimilar treatments will bring benefits to patients and better serve these communities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze